614 completed. 614 Phase 2, 67 Phase 1, 46 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 614 | Completed 614 |
| Phase 1 | 67 | Completed 67 |
| Phase 3 | 46 | Completed 46 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D hepalatide - Hepatitis D | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 90 | 2024-12-11 | 2026-10-29 |
| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) ADX-629 - Alcohol Hepatitis | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 4 | 2024-11-04 | 2026-06-03 |
| Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). AHB-137 (24 weeks), AHB-137 and Placebo, AHB-137 (16 weeks) - Hepatitis B, Chronic | Phase 2 | Completed | Ausper Biopharma Co., Ltd. | 86 | 2024-07-10 | 2026-09-15 |
| A Study of RBD1016 in CHB Participants RBD1016 - Chronic Hepatitis b | Phase 2 | Completed | Suzhou Ribo Life Science Co. Ltd. | 48 | 2023-10-11 | 2025-12-09 |
| Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Hepalatide, Hepalatide Placebo - Chronic Hepatitis D Infection | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 23 | 2023-10-07 | 2024-04-24 |
| Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients PEG-IFNα, BRII-835 - Chronic Hepatitis B Virus Infection | Phase 2 | Completed | Brii Biosciences Limited | 86 | 2023-08-22 | 2026-10-20 |
| A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients AHB-137 injection, Placebo - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Ausper Biopharma Co., Ltd. | 129 | 2023-08-03 | 2026-05-07 |
| A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) HRS9950 tablets, HRS9950 placebo tablets - Chronic Hepatitis B | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 54 | 2023-07-28 | 2024-12-03 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) zetomipzomib, placebo, zetomipzomib in open-label extension - Autoimmune Hepatitis | Phase 2 | Completed | Kezar Life Sciences, Inc. | 24 | 2023-05-23 | 2026-01-13 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection VIR-3434, VIR-2218, TDF - Hepatitis B, Chronic | Phase 1 / Phase 2 | Completed | Vir Biotechnology, Inc. | 33 | 2023-05-10 | 2026-02-09 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets GST-HG141 - Chronic Hepatitis b | Phase 2 | Completed | Fujian Akeylink Biotechnology Co., Ltd. | 90 | 2023-01-03 | 2025-03-05 |
| A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. HR19042 Capsules - Autoimmune Hepatitis | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 69 | 2022-10-06 | 2025-03-24 |
| Efficacy of VTP-300 in Chronic Hepatitis B Infection ChAdOx1-HBV, MVA-HBV, Nivolumab - Chronic Hepatitis B | Phase 2 | Completed | Barinthus Biotherapeutics | 121 | 2022-09-21 | 2026-04-30 |
| A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets - Chronic Hepatitis B | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 8 | 2022-08-23 | 2024-07-15 |
| An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil - Hepatitis B, Chronic | Phase 2 | Completed | Janssen Research & Development, LLC | 37 | 2022-06-30 | 2025-04-25 |
| A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy GSK3228836, GSK3528869A, Control - Hepatitis B, Chronic | Phase 2 | Completed | GlaxoSmithKline | 174 | 2022-03-22 | 2025-12-30 |
| Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV ASC42 10mg, ASC42 15mg, ih PEG-IFN α-2a - Hepatitis B, Chronic | Phase 2 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 43 | 2022-01-10 | 2024-04-04 |
| Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone MTL-CEBPA, Sorafenib - Hepatocellular Carcinoma, Hepatitis B | Phase 2 | Completed | Mina Alpha Limited | 8 | 2022-01-01 | 2025-03-06 |
Showing 20 of 614. Sign in to see all of them.
Hepatitis C (267) · Hepatitis C, Chronic (194) · Hepatitis B (101) · Hepatitis B, Chronic (94) · HIV Infections (32) · Fibrosis (23) · Liver Diseases (21) · Tetanus (19) · Diphtheria (18) · Haemophilus Infections (15) · Hepatitis, Alcoholic (15) · Poliomyelitis (14) · Hepatitis, Chronic (11) · Liver Cirrhosis (11)
Digestive System Diseases (612) · Liver Diseases (593) · Infections (577) · Hepatitis, Viral, Human (573) · Virus Diseases (570) · Blood-Borne Infections (557) · Communicable Diseases (554) · RNA Virus Infections (432) · Flaviviridae Infections (388) · Pathological Conditions, Signs and Symptoms (331) · Pathologic Processes (329) · Disease Attributes (304) · Chronic Disease (302) · Hepatitis, Chronic (298)
Ribavirin (201) · peginterferon alfa-2a (116) · Sofosbuvir (49) · entecavir (28) · Ritonavir (27) · peginterferon alfa-2b (27) · daclatasvir (26) · Tenofovir (25) · ledipasvir, sofosbuvir drug combination (24) · Simeprevir (19) · grazoprevir (17) · paritaprevir (17) · sofosbuvir-velpatasvir drug combination (17) · telaprevir (17) · ombitasvir (15)
Gilead Sciences (70) · Merck Sharp & Dohme LLC (36) · GlaxoSmithKline (35) · Bristol-Myers Squibb (31) · National Institute of Allergy and Infectious Diseases (NIAID) (22) · Hoffmann-La Roche (21) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (17) · AbbVie (14) · Vertex Pharmaceuticals Incorporated (13) · AbbVie (prior sponsor, Abbott) (11) · ANRS, Emerging Infectious Diseases (10) · Boehringer Ingelheim (9) · Janssen Research & Development, LLC (8) · French National Agency for Research on AIDS and Viral Hepatitis (7) · Romark Laboratories L.C. (7)
United States (281) · France (90) · Germany (88) · Canada (71) · Puerto Rico (66) · United Kingdom (64) · New Zealand (55) · China (51) · Spain (51) · Australia (45) · Belgium (45) · Italy (42) · South Korea (40) · Taiwan (38) · Poland (34)
Robert H. Hyland, DPhil (5) · Asem Elfert, MD (4) · Daniel Cohen, MD (4) · Marc G Ghany, M.D. (4)
PMID 28193518, PMID 30012435, PMID 30664876, PMID 30923816, PMID 30977945, PMID 37011138, PMID 20657177, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 27257978, PMID 28340322, PMID 28412293, PMID 28802814, PMID 28802816, PMID 30850240, PMID 31568620, PMID 35179437, PMID 39950613, PMID 41042426, PMID 11605686, PMID 12620148, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15763232, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16871563, PMID 16987047, PMID 17058225, PMID 17058240, PMID 17109339, PMID 17147494, PMID 17200799, PMID 17263626, PMID 17329696
2014 (15), 2016 (11), 2009 (9), 2015 (9), 2019 (7), 2008 (4), 2017 (3), 2004 (2), 2023 (2), R01DA026727 (2), U01AA021886 (2), 2005 (1), 2018 (1), N01CN35160 (1), P01AI055793 (1)